Rapid Readouts

Tycel Phillips, MD, discusses a phase 1/2 trial combining subcutaneous epcoritamab with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.

Dr Smith reviews post-hoc data from the OPTIC trial which assessed the safety and efficacy of ponatinib in patients with CP-CML whose disease was resistant to 2 or more TKIs or who have a T3151 mutation.

Expert hematologist/oncologist Joseph Mikhael, MD, shares insight on the phase III GMMG-HD7 trial, which added isatuximab to RVd in the setting of newly diagnosed, transplant-eligible multiple myeloma.

Leon Bernal-Mizrachi, MD, discusses efficacy and safety updates to the US MM-6 study that was presented at the ASH 63rd Annual Meeting in 2021, as well as reasons for premature discontinuation, for patients with newly diagnosed multiple myeloma (NDMM).

Thomas G. Martin, MD, explains the updated results from CARTITUDE-1, a clinical trial that studied ciltacabtagene autoleucal in patients with relapsed/refractory multiple myeloma, that were presented at the ASH 63rd Annual Meeting in 2021.

Anthony Mato, MD, discusses updated efficacy and safety results from the phase 1/2 BRUIN study of the noncovalent BTK inhibitor, pirtobrutinib, in patients with previously treated CLL/SLL that was presented at the American Society of Hematology 2021 Annual Meeting.

Tycel Phillips, MD, discusses EPCORE DLBCL-1, a phase trial that focused on testing epcoritamab against other regiments for patients with relapsed or refractory diffuse large B-cell lymphoma, as presented at the 63rd ASH Annual Meeting in 2021.

Michael L. Wang, MD, discusses the updated results from the Phase 1/2 BRUIN clinical trial, which focused on the use of pirtobrutinib in previously treated mantle cell lymphoma.

Frederick L. Locke, MD, discusses the results from the ZUMA-7 clinical trial that focused on axicabtagene ciloleucel, as presented at the 63rd ASH Annual Meeting in 2021.

Pau Montesinos, MD, PhD, discusses the AGILE phase 3 clinical trial for newly diagnosed patients with acute myeloid leukemia with an IDH1 mutation that was presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition in 2021, from study designs to data results.

Eytan Stein, MD, discusses the AUGMENT-101 trial and menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia, which was presented at the 63rd ASH Annual Meeting in 2021.

Moshe Yair Levy, MD, discusses the safety and efficacy in a phase 2 trial that focused on naratuximab emtansine plus rituximab for the treatment of B-cell lymphomas, as presented at the 63rd ASH Annual Meeting in 2021.

Expert perspectives on the phase II clinical trial assessing IRV triplet therapy in young patients with previously untreated mantle cell lymphoma to help minimize chemotherapy exposure.

Dr Bachelot, MD, PhD, presents updated results from the HER2CLIMB trial of tucatinib plus trastuzumab and capecitabine versus placebo plus trastuzumab and capecitabine in patients with HER2-positive breast cancer with brain metastases.

Matthew Davids, MD, MMsc, provides preliminary information on the MAJIC trial from his ASH 2021 presentation, which will focus on the comparison of venetoclax combined with acalabrutinib and obinutuzumab, respectfully, for the treatment of CLL or SLL.

Matthew Davids, MD, MMsc, presents John F. Seymour, MBBS, FRACP, PhD’s presentation from ASH 2021 on BTKI-related adverse events in the ELEVATE-RR trial that observed acalabrutinib vs ibrutinib for previously treated CLL.

Sara A. Hurvitz, MD, discusses findings from the DESTINY-BREAST03 trial that were presented at the 2021 San Antonio Breast Cancer Symposium that compare trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) for patients with HER2+ metastatic breast cancer.

Jonathan E. Brammer, MD, reports data presented at the 2021 American Society of Hematology Annual Meeting regarding interim analysis study results from the phase 2 PRIMO trial evaluating the use of duvelisib monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma.

Dr Carrie Lynn Kitko discusses updated results from a phase 1/2 study evaluating the safety, tolerability, and efficacy of axatilimab in pts ≥ 6 years of age with active cGVHD despite ≥ 2 prior lines of systemic therapy.

Afshin Dowlati, MD, discusses data from the following presentation: “Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study.” (Paz-Ares, ESMO 2021, LBA61)

Alexander Drilon, MD, discusses prior therapy and performance status outcomes for larotrectinib in patients with non-CNS TRK fusion cancer that were presented at the European Society of Medical Oncology 2021 annual meeting.

Alexander Drilon, MD, discusses the efficacy and safety data of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion-positive lung cancer that was presented at the World Cancer Lung Conference 2021 annual meeting.

Virginia Kaklamani, MD, DSc, presents results of the DESTINY-Breast03 clinical trial of trastuzumab deruxtecan compared with trastuzumab emtansine as treatment for patients with HER2-positive metastatic breast cancer.

Ronan Kelly, MD, MBA, discusses data from the presentation “Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen.” (Van Cutsem et al, ESMO 2021, LBA55)

William G. Wierda, MD, discusses data from the phase 1 cohort of lisocabtagene maraleucel combined with ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic leukemia that was presented at the 19th International Workshop on CLL (iwCLL) held in September 2021.

Expert Riad Salem, MD, MBA, highlights key data from the phase 3 EPOCH study, which evaluated TheraSphere in patients with mCRC and liver metastases who failed first line chemotherapy.

Andrew J. Armstrong, MD, discusses final overall survival data from the phase 3 randomized, double-blind, placebo-controlled ARCHES study of enzalutamide plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer presented at the European Society for Medical Oncology 2021 Congress.

Dr Zhang, MD, discusses cognitive assessment data from patients with metastatic castrate-resistant prostate cancer in the ODENZA trial receiving either darolutamide or enzalutamide that was presented at the European Society for Medical Oncology 2021 Annual Meeting.

A. Timothy Schmidt, MD, discusses data from the subgroup analysis of the IKEMA study of isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma and high-risk cytogenetics that was presented at the American Society of Clinical (ASCO) 2021 Annual Meeting.

Expert oncologist Giuseppe Curigliano, MD, PhD, reflects on the updated results of the HER2CLIMB study evaluating tucatinib against placebo, each in combination with trastuzumab and capecitabine, in patients with pretreated HER2+ metastatic breast cancer.